Trastuzumab-resistant HER2 þ breast cancer cells retain sensitivity to poly (adp-ribose) polymerase (parp) inhibition

Academic Article

Abstract

  • © 2018 American Association for Cancer Research. HER2-targeted therapies, such as trastuzumab, have increased the survival rates of HER2 þ breast cancer patients. However, despite these therapies, many tumors eventually develop resistance to these therapies. Our lab previously reported an unexpected sensitivity of HER2 þ breast cancer cells to poly (ADP-ribose) polymerase inhibitors (PARPi), agents that target homologous recombination (HR)–deficient tumors, independent of a DNA repair deficiency. In this study, we investigated whether HER2 þ trastuzumab-resistant (TR) breast cancer cells were susceptible to PARPi and the mechanism behind PARPi induced cytotoxicity. We demonstrate that the PARPi ABT-888 (veliparib) decreased cell survival in vitro and tumor growth in vivo of HER2 þ TR breast cancer cells. PARP-1 siRNA confirmed that cytotoxicity was due, in part, to PARP-1 inhibition. Furthermore, PARP-1 silencing had variable effects on the expression of several NF-kB–regulated genes. In particular, silencing PARP-1 inhibited NF-kB activity and reduced p65 binding at the IL8 promoter, which resulted in a decrease in IL8 mRNA and protein expression. Our results provide insight in the potential mechanism by which PARPi induces cytotoxicity in HER2 þ breast cancer cells and support the testing of PARPi in patients with HER2 þ breast cancer resistant to trastuzumab.
  • Published In

    Digital Object Identifier (doi)

    Author List

  • Wielgos ME; Zhang Z; Rajbhandari R; Cooper TS; Zeng L; Forero A; Esteva FJ; Kent Osborne C; Schiff R; LoBuglio AF
  • Start Page

  • 921
  • End Page

  • 930
  • Volume

  • 17
  • Issue

  • 5